Apixaban After the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis With First-Line Therapy–Extended Treatment - AMPLIFY-EXT

Description:

The goal of the trial was to evaluate treatment with apixaban, a factor Xa inhibitor, compared with placebo among patients with venous thromboembolism who had completed 6-12 months of anticoagulation therapy.